GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroOne Medical Technologies Corp (NAS:NMTC) » Definitions » Operating Income

NeuroOne Medical Technologies (NeuroOne Medical Technologies) Operating Income : $-13.56 Mil (TTM As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is NeuroOne Medical Technologies Operating Income?

NeuroOne Medical Technologies's Operating Income for the three months ended in Dec. 2023 was $-3.39 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-13.56 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. NeuroOne Medical Technologies's Operating Income for the three months ended in Dec. 2023 was $-3.39 Mil. NeuroOne Medical Technologies's Revenue for the three months ended in Dec. 2023 was $0.98 Mil. Therefore, NeuroOne Medical Technologies's Operating Margin % for the quarter that ended in Dec. 2023 was -346.63%.

NeuroOne Medical Technologies's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NeuroOne Medical Technologies's annualized ROC % for the quarter that ended in Dec. 2023 was -903.70%. NeuroOne Medical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -958.64%.


NeuroOne Medical Technologies Operating Income Historical Data

The historical data trend for NeuroOne Medical Technologies's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroOne Medical Technologies Operating Income Chart

NeuroOne Medical Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.81 -4.90 -10.22 -10.03 -11.96

NeuroOne Medical Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.78 -3.50 -3.51 -3.17 -3.39

NeuroOne Medical Technologies Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeuroOne Medical Technologies  (NAS:NMTC) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NeuroOne Medical Technologies's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-13.56 * ( 1 - 0% )/( (1.111 + 1.89)/ 2 )
=-13.56/1.5005
=-903.70 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

NeuroOne Medical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-13.56/( ( (0.695 + max(0.327, 0)) + (0.645 + max(1.162, 0)) )/ 2 )
=-13.56/( ( 1.022 + 1.807 )/ 2 )
=-13.56/1.4145
=-958.64 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 1.727 + 0.264) - (1.664 + 0 + 0)
=0.327

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.543 + 1.609 + 0.26) - (1.251 + 0 + -0.00099999999999989)
=1.162

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

NeuroOne Medical Technologies's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-3.39/0.978
=-346.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


NeuroOne Medical Technologies Operating Income Related Terms

Thank you for viewing the detailed overview of NeuroOne Medical Technologies's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroOne Medical Technologies (NeuroOne Medical Technologies) Business Description

Traded in Other Exchanges
N/A
Address
7599 Anagram Dr., Eden Prairie, MN, USA, 55344
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Executives
Mark Christianson 10 percent owner, officer: VP, Business Dev and Marketing 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Ronald W. Mcclurg officer: Chief Financial Officer C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa director, officer: CEO and President 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Hijaz Haris officer: VP of Marketing C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
Morgan C. Frank 10 percent owner 2 CALLE NAIRN, UNIT 701, SAN JUAN PR 00907
Manchester Management Co Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02110
Manchester Explorer, L.p. 10 percent owner MANCHESTER MANAGEMENT COMPANY, L.L.C, 3 WEST HILL PLACE, Boston ma 02114
James E Besser 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Manchester Management Pr, Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Edward Andrle director C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DRIVE, EDEN PRAIRIE MN 55344
Wade Fredrickson 10 percent owner 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Steve Mertens officer: Chief Technology Officer 10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Scott Heuler officer: Vice President of Sales 10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Paul Buckman director 12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Suraj Kalia director 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347